Listen to the article
Securities Class Action Filed Against ImmunityBio and Executive Chairman Over Alleged Misleading Drug Claims
Investors in ImmunityBio, Inc. (NASDAQ: IBRX) are facing significant losses following revelations that promotional communications about the company’s lead drug allegedly violated FDA regulations. According to a securities class action lawsuit filed in New York, the company’s share price dropped 21 percent after federal regulators determined that statements about the drug ANKTIVA were false or misleading.
The stock fell $1.98 per share to close at $7.42 on March 24, 2026, following the publication of an FDA Warning Letter concerning the promotional claims. The lawsuit covers investors who purchased shares between January 19 and March 24, 2026.
Unlike many securities class actions that target only the corporate entity, this lawsuit specifically names Dr. Patrick Soon-Shiong, ImmunityBio’s Executive Chairman and Global Chief Scientific and Medical Officer, as an individual defendant. Legal experts note this represents a significant escalation in potential liability for corporate executives who make public statements about regulated products.
“This case highlights the personal accountability that can attach to senior executives who make promotional claims about pharmaceutical products,” said securities attorney Rebecca Martinez, who is not affiliated with the case. “The FDA has strict rules about drug promotion, and violations can trigger not just regulatory consequences but also securities litigation.”
The lawsuit alleges that Soon-Shiong directly participated in making the statements in question during an appearance on a nationally broadcast podcast where he allegedly made false claims about ANKTIVA. As the company’s scientific and medical officer, Soon-Shiong had particular responsibility for ensuring the accuracy of public statements about ImmunityBio’s products.
Legal claims in the case are brought under Section 20(a) of the Securities Exchange Act of 1934, which establishes liability for individuals who control companies that violate securities laws. The complaint argues that Soon-Shiong’s dual roles gave him authority over both corporate strategy and scientific communications, placing him in a position of direct oversight regarding the company’s public statements.
The lawsuit further asserts that Soon-Shiong failed to fulfill his duty as a senior officer of a publicly traded company to ensure the dissemination of accurate and truthful information regarding the company’s operations and prospects.
Biotech industry analysts suggest this case reflects a broader trend of increased scrutiny on promotional communications in the pharmaceutical sector. “The FDA has been increasingly vigilant about policing drug promotional claims, especially when they involve unapproved indications or exaggerated efficacy claims,” noted pharmaceutical market researcher Dr. James Holloway.
ImmunityBio is a clinical-stage immunotherapy company developing treatments for cancer and infectious diseases. ANKTIVA, the drug at the center of the controversy, represents a significant portion of the company’s developmental pipeline and market valuation.
The Court has established May 26, 2026, as the deadline for investors to apply for appointment as lead plaintiff in the case. Under the Private Securities Litigation Reform Act, courts typically appoint the investor with the largest financial loss who is willing to serve as the representative for all class members.
Law firm Levi & Korsinsky, which filed the lawsuit, is actively seeking affected investors. The firm notes that participation in securities class actions involves no upfront costs for investors, as such cases are handled on a contingency basis.
The case represents another example of the ongoing tension between biotechnology companies eager to promote their pipeline products and strict regulatory frameworks that govern communications about drugs that have not yet received full FDA approval or are approved for limited indications.
Neither ImmunityBio nor Dr. Soon-Shiong has publicly responded to the allegations as of this report.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
6 Comments
It’s troubling to see allegations of securities fraud against a biotech company. Transparency and accuracy in communications around drug development are critical for maintaining investor trust. This lawsuit seems like a significant escalation.
While the details are still emerging, the allegations of misleading claims around ImmunityBio’s lead drug are concerning. Investors will be closely watching to see how the company addresses these issues and restores confidence.
The FDA warning letter and resulting stock drop highlight the importance of careful, compliant promotion of regulated products. It will be interesting to follow how this case develops and what lessons can be learned for other biotech firms.
This lawsuit is a stark reminder that biotech companies must navigate a complex regulatory landscape. Careful communication and transparency are essential to maintain credibility and shareholder trust.
Naming the executive chairman as an individual defendant is an unusual move that could increase personal liability. This case underscores the need for corporate leaders to exercise diligence in their public statements on regulated products.
This is a concerning development for ImmunityBio investors. Misleading claims about regulated drugs can have serious legal and financial consequences. I’m curious to see how the company and its leadership respond to the allegations.